药物对比
Canagliflozin vs Troglitazone
Canagliflozin与Troglitazone治疗糖尿病的比较：SGLT2抑制剂与噻唑烷二酮类。Troglitazone因肝毒性已撤市。比较机制、安全性及可获得性。
此页面暂无可用的对比维度。
临床背景
This comparison occurs when evaluating modern SGLT2 inhibitors against historical thiazolidinediones withdrawn for safety in type 2 diabetes care.
结论
Canagliflozin is the only currently viable option of the two due to Troglitazone's market withdrawal.
全部药物对比